Skip to main content

Human CD4-Binding Site Antibody Elicited by Polyvalent DNA Prime-Protein Boost Vaccine Neutralizes Cross-Clade Tier-2-HIV Strains.

Publication ,  Journal Article
Wang, S; Chan, K-W; Wei, D; Ma, X; Liu, S; Hu, G; Park, S; Pan, R; Gu, Y; Nazzari, AF; Olia, AS; Xu, K; Lin, BC; Louder, MK; Doria-Rose, NA ...
Published in: Res Sq
October 20, 2023

The vaccine elicitation of HIV-neutralizing antibodies with tier-2-neutralization breadth has been a challenge. Here, we report the isolation and characteristics of a CD4-binding site specific monoclonal antibody, HmAb64, from a human volunteer immunized with a polyvalent gp120 DNA prime-protein boost vaccine. HmAb64 derived from heavy chain variable germline gene IGHV1-18, light chain germline gene IGKV1-39, and had a 3rd heavy chain complementarity determining region (CDR H3) of 15 amino acids. On a cross-clade panel of 208 HIV-1 pseudo-virus strains, HmAb64 neutralized 21 (10%), including tier-2 neutralization resistant strains from clades B, BC, C, and G. The cryo-EM structure of the antigen-binding fragment of HmAb64 bound to a conformation between prefusion closed and occluded open forms of envelope trimer, using both heavy and light CDR3s to recognize the CD4-binding loop, a critical component of the CD4-binding site. A gp120 subunit-based vaccine can thus elicit an antibody capable of tier 2-HIV neutralization.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Res Sq

DOI

EISSN

2693-5015

Publication Date

October 20, 2023

Location

United States
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wang, S., Chan, K.-W., Wei, D., Ma, X., Liu, S., Hu, G., … Lu, S. (2023). Human CD4-Binding Site Antibody Elicited by Polyvalent DNA Prime-Protein Boost Vaccine Neutralizes Cross-Clade Tier-2-HIV Strains. Res Sq. https://doi.org/10.21203/rs.3.rs-3360161/v1
Wang, Shixia, Kun-Wei Chan, Danlan Wei, Xiuwen Ma, Shuying Liu, Guangnan Hu, Saeyoung Park, et al. “Human CD4-Binding Site Antibody Elicited by Polyvalent DNA Prime-Protein Boost Vaccine Neutralizes Cross-Clade Tier-2-HIV Strains.Res Sq, October 20, 2023. https://doi.org/10.21203/rs.3.rs-3360161/v1.
Wang, Shixia, et al. “Human CD4-Binding Site Antibody Elicited by Polyvalent DNA Prime-Protein Boost Vaccine Neutralizes Cross-Clade Tier-2-HIV Strains.Res Sq, Oct. 2023. Pubmed, doi:10.21203/rs.3.rs-3360161/v1.
Wang S, Chan K-W, Wei D, Ma X, Liu S, Hu G, Park S, Pan R, Gu Y, Nazzari AF, Olia AS, Xu K, Lin BC, Louder MK, Doria-Rose NA, Montefiori D, Seaman MS, Zhou T, Kwong PD, Arthos J, Kong X-P, Lu S. Human CD4-Binding Site Antibody Elicited by Polyvalent DNA Prime-Protein Boost Vaccine Neutralizes Cross-Clade Tier-2-HIV Strains. Res Sq. 2023 Oct 20;

Published In

Res Sq

DOI

EISSN

2693-5015

Publication Date

October 20, 2023

Location

United States